Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $27 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $27 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $23 | $28 | $27 | $33 |
| G&A Expenses | $11 | $7 | $11 | $40 |
| SG&A Expenses | $11 | $7 | $11 | $40 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $8 | $4 |
| Operating Expenses | $34 | $36 | $46 | $77 |
| Operating Income | -$34 | -$36 | -$46 | -$50 |
| % Margin | – | – | – | -185.6% |
| Other Income/Exp. Net | $7 | $9 | -$3 | $2 |
| Pre-Tax Income | -$27 | -$27 | -$48 | -$48 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$27 | -$27 | -$48 | -$47 |
| % Margin | – | – | – | -176.7% |
| EPS | -0.37 | -0.37 | -0.67 | -0.67 |
| % Growth | 0% | 44.8% | 0% | – |
| EPS Diluted | -0.37 | -0.37 | -0.67 | -0.67 |
| Weighted Avg Shares Out | 72 | 72 | 72 | 71 |
| Weighted Avg Shares Out Dil | 72 | 72 | 72 | 71 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$27 | -$35 | -$38 | -$46 |
| % Margin | – | – | – | -170.5% |